Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma - PubMed (original) (raw)
. 2004 May 1;103(9):3521-8.
doi: 10.1182/blood-2003-10-3650. Epub 2004 Jan 8.
Affiliations
- PMID: 14715624
- DOI: 10.1182/blood-2003-10-3650
Free article
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma
Suzanne Trudel et al. Blood. 2004.
Free article
Abstract
We have previously shown that dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the t(4;14) translocation is a primary event in multiple myeloma (MM) and that activating mutations of FGFR3 are acquired in some cases. We describe here inhibition of wild-type (WT) and constitutively activated mutant FGFR3 autophosphorylation by the small molecule inhibitor, PD173074. Inhibition of FGFR3 in human myeloma cell lines was associated with decreased viability and tumor cell growth arrest. Further, morphologic, phenotypic, and functional changes typical of plasma cell (PC) differentiation, including increase in light-chain secretion and expression of CD31, were observed and this was followed by apoptosis. Finally, using a mouse model of FGFR3 myeloma, we demonstrate a delay in tumor progression and prolonged survival of mice treated with PD173074. These results indicate that inhibition of FGFR3, even in advanced disease associated with multiple genetic changes, may allow the cell to complete its developmental program and render it sensitive to apoptotic signals. In addition, this represents the validation of a therapeutic target in MM that may benefit patients who have a very poor prognosis with currently available treatments.
Similar articles
- Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Grand EK, et al. Leukemia. 2004 May;18(5):962-6. doi: 10.1038/sj.leu.2403347. Leukemia. 2004. PMID: 15029211 - Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK. Plowright EE, et al. Blood. 2000 Feb 1;95(3):992-8. Blood. 2000. PMID: 10648414 - Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Slovak ML, Liu X, Luo J, Yen Y. Zhu L, et al. Mol Cancer Ther. 2005 May;4(5):787-98. doi: 10.1158/1535-7163.MCT-04-0330. Mol Cancer Ther. 2005. PMID: 15897243 - The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
Chesi M, Bergsagel PL, Kuehl WM. Chesi M, et al. Curr Opin Hematol. 2002 Jul;9(4):288-93. doi: 10.1097/00062752-200207000-00005. Curr Opin Hematol. 2002. PMID: 12042702 Review. - Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.
L'Hôte CG, Knowles MA. L'Hôte CG, et al. Exp Cell Res. 2005 Apr 1;304(2):417-31. doi: 10.1016/j.yexcr.2004.11.012. Epub 2004 Dec 16. Exp Cell Res. 2005. PMID: 15748888 Review.
Cited by
- Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.
Kotani N, Ishiura Y, Yamashita R, Ohnishi T, Honke K. Kotani N, et al. J Biol Chem. 2012 Oct 26;287(44):37109-18. doi: 10.1074/jbc.M112.404178. Epub 2012 Aug 29. J Biol Chem. 2012. PMID: 22932894 Free PMC article. - Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.
Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A. Hafner C, et al. J Clin Invest. 2006 Aug;116(8):2201-2207. doi: 10.1172/JCI28163. J Clin Invest. 2006. PMID: 16841094 Free PMC article. - FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
Tomlinson DC, Baldo O, Harnden P, Knowles MA. Tomlinson DC, et al. J Pathol. 2007 Sep;213(1):91-8. doi: 10.1002/path.2207. J Pathol. 2007. PMID: 17668422 Free PMC article. - Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams.
Pan D, Richter J. Pan D, et al. Front Oncol. 2022 Jan 20;11:819127. doi: 10.3389/fonc.2021.819127. eCollection 2021. Front Oncol. 2022. PMID: 35127532 Free PMC article. Review. - Preclinical studies of novel targeted therapies.
Hideshima T, Anderson KC. Hideshima T, et al. Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix. doi: 10.1016/j.hoc.2007.08.013. Hematol Oncol Clin North Am. 2007. PMID: 17996589 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical